These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18681190)

  • 1. Quality of life, symptomatology and healthcare utilization in HIV/HCV co-infected drug users in Miami.
    Baum MK; Jayaweera DT; Duan R; Sales S; Lai S; Rafie C; Regev A; Page JB; Berkman R; Campa A
    J Addict Dis; 2008; 27(2):37-48. PubMed ID: 18681190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Health related quality of life among HIV-HCV co-infected patients].
    Préau M; Protopopescu C; Spire B; Dellamonica P; Poizot-Martin I; Villes V; Carrieri MP;
    Rev Epidemiol Sante Publique; 2006 Jul; 54 Spec No 1():1S33-1S43. PubMed ID: 17073128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-Related Quality of Life in HIV-Infected and At-Risk Women: The Impact of Illicit Drug Use and Hepatitis C on a Community Preference Weighted Measure.
    Aden B; Nosyk B; Wittenberg E; Schackman BR
    Med Decis Making; 2014 Aug; 34(6):800-8. PubMed ID: 24106234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
    Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T
    Liver Int; 2014 Jan; 34(1):69-77. PubMed ID: 23890125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
    Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
    Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Social determinants of health associated with hepatitis C co-infection among people living with HIV: results from the Positive Spaces, Healthy Places study.
    Rourke SB; Sobota M; Tucker R; Bekele T; Gibson K; Greene S; Price C; Koornstra JJ; Monette L; Byers S; Watson J; Hwang SW; Guenter D; Dunn J; Ahluwalia A; Wilson MG; Bacon J;
    Open Med; 2011; 5(3):e120-31. PubMed ID: 22046224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study.
    Bailey H; Nizova N; Martsynovska V; Volokha A; Malyuta R; Cortina-Borja M; Thorne C;
    BMC Infect Dis; 2016 Dec; 16(1):755. PubMed ID: 27955711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Underlying pathophysiology of HCV infection in HIV-positive drug users.
    Balasubramanian A; Groopman JE; Ganju RK
    J Addict Dis; 2008; 27(2):75-82. PubMed ID: 18681194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone.
    Braitstein P; Li K; Kerr T; Montaner JS; Hogg RS; Wood E
    AIDS Care; 2006 Oct; 18(7):690-3. PubMed ID: 16971276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: outcomes from a population-based cohort.
    Braitstein P; Montessori V; Chan K; Montaner JS; Schechter MT; O'Shaughnessy MV; Hogg RS
    AIDS Care; 2005 May; 17(4):505-15. PubMed ID: 16036236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
    Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
    Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevalence of hepatitis C virus among HIV-infected patients in Area 2 of Madrid].
    González Cerrajero M; Pazos García A; de los Santos Gil I; Sanz Sanz J
    An Med Interna; 2006 Mar; 23(3):111-4. PubMed ID: 16737430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.
    Patel EU; Solomon SS; Mcfall AM; Srikrishnan AK; Pradeep A; Nandagopal P; Laeyendecker O; Tobian AAR; Thomas DL; Sulkowski MS; Kumar MS; Mehta SH
    Int J Drug Policy; 2018 Jul; 57():51-60. PubMed ID: 29679811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
    Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
    Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
    Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
    Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations.
    Backus LI; Boothroyd D; Deyton LR
    AIDS; 2005 Oct; 19 Suppl 3():S13-9. PubMed ID: 16251809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of human immunodeficiency virus type 1 and hepatitis C virus among injection drug users who use high risk inner-city locales in Miami, Florida.
    McCoy CB; Metsch LR; Collado-Mesa F; Arheart KL; Messiah SE; Katz D; Shapshak P
    Mem Inst Oswaldo Cruz; 2004 Dec; 99(8):789-93. PubMed ID: 15761592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study.
    Martel-Laferrière V; Nitulescu R; Cox J; Cooper C; Tyndall M; Rouleau D; Walmsley S; Wong L; Klein MB;
    BMC Infect Dis; 2017 Jan; 17(1):80. PubMed ID: 28095797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    Su S; Fairley CK; Sasadeusz J; He J; Wei X; Zeng H; Jing J; Mao L; Chen X; Zhang L
    J Med Virol; 2018 Mar; 90(3):518-525. PubMed ID: 29091279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients.
    Nilsson J; Weiland O
    Scand J Infect Dis; 2010 Jul; 42(6-7):533-9. PubMed ID: 20214543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.